Zealand Pharma : Des relais de croissance au-delà du partenariat avec Sanofi
>Un newsflow clinique dense au S2 - Zealand Pharma a communiqué la semaine dernière ses résultats financiers au titre du T2 2018. Le revenu composé des royalties de la coopération avec Sanofi s’élèvent à 2.4 M$ (15.1 MDKK, +65% yoy) dont 1.8 M$ (11.5 MDKK vs 3.9 MDKK au T2 2017) pour Soliqua et 0.6 M$ (3.6 MDKK vs 5.2 MDKK en 2017) pour Lyxumia. La perte opérationnelle se creuse à -131.9 MDKK (vs -95.4 MDKK en 2017) pour un résultat net de -127.1 MDKK. En terme de n...Zealand Pharma is a biotechnology company. Co. is engaged in the discovery development and commercialization of peptide-based medicines. Co.'s pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area are ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.